| 1 |
Actemra, mra |
- |
- |
- |
- |
107 1件: 107 💬 |
| 2 |
Mra |
- |
- |
- |
- |
046 2件: 46, 107 💬 |
| 3 |
Mra (actemra) |
- |
- |
- |
- |
107 1件: 107 💬 |
| 4 |
Mra (tocilizumab) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 107 💬 |
| 5 |
Mra 003 us |
- |
- |
- |
- |
049 1件: 49 💬 |
| 6 |
Mra(tocilizumab) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 2件: 46, 107 💬 |
| 7 |
Mra, actemra |
- |
- |
- |
- |
046 2件: 46, 107 💬 |
| 8 |
Mra-sc |
- |
- |
- |
- |
046 1件: 46 💬 |
| 9 |
Tocilizumab (mra-sc) |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
040 1件: 40 💬 |